The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight [Yahoo! Finance]
NervGen Pharma Corp. - Common stock (NGEN)
Company Research
Source: Yahoo! Finance
Pharma), Neuro-Cells (Neuroplast), MT-3921 (Mitsubishi Tanabe Pharma America), Elezanumab (AbbVie), PMZ-1620 (Pharmazz), NFX88 (Neurofix), NVG-291 (NervGen Pharma), and others. The introduction of these innovative spinal cord injury therapies is expected to revolutionize the SCI treatment landscape in the coming years. New York, USA, April 02, 2026 (GLOBE NEWSWIRE) The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight The SCI treatment pipeline continues to expand, featuring candidates such as KP-100IT (Kringle Pharma), Neuro-Cells (Neuroplast), MT-3921 (Mitsubishi Tanabe Pharma America), Elezanumab (AbbVie), PMZ-1620 (Pharmazz), NFX88 (Neurofix), NVG-291 (NervGen Pharma), and others. The introduction of these innovative spinal cord injury therapies is expected to revolutionize the SCI treatment landscape in the coming years. The spinal cord injury treatment landscape stands at a critical juncture. Despite the devastating impact on millions
Show less
Read more
Impact Snapshot
Event Time:
NGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGEN alerts
High impacting NervGen Pharma Corp. - Common stock news events
Weekly update
A roundup of the hottest topics
NGEN
News
- NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewswire
- NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic TetraplegiaGlobeNewswire
- NervGen Pharma FY GAAP EPS of -$0.61 [Seeking Alpha]Seeking Alpha
- NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates [TheStreet.com]TheStreet.com
NGEN
Sec Filings
- 3/31/26 - Form 40-F
- 3/13/26 - Form 6-K
- 2/13/26 - Form 6-K
- NGEN's page on the SEC website